Treatment of refractory diabetic macular edema with a fluocinolone acetonide implant in vitrectomized and non-vitrectomized eyes
AIM: To report real-life data on the use of an intravitreal fluocinolone acetonide implant in the treatment of refractory diabetic macular edema (DME) in pars plana vitrectomized (PPV) and non-PPV eyes. METHODS: This was a comparative retrospective observational study of 23 eyes with chronic DME. B...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Press of International Journal of Ophthalmology (IJO PRESS)
2018-12-01
|
Series: | International Journal of Ophthalmology |
Subjects: | |
Online Access: | http://www.ijo.cn/en_publish/2018/12/20181213.pdf |
id |
doaj-bb40d69dad644f13b2bb029d12430f19 |
---|---|
record_format |
Article |
spelling |
doaj-bb40d69dad644f13b2bb029d12430f192020-11-25T00:37:55ZengPress of International Journal of Ophthalmology (IJO PRESS)International Journal of Ophthalmology2222-39592227-48982018-12-0111121951195610.18240/ijo.2018.12.13Treatment of refractory diabetic macular edema with a fluocinolone acetonide implant in vitrectomized and non-vitrectomized eyesAlberto La Mantia0Alan Hawrami1Heidi Laviers2Sudeshna Patra3Hadi Zambarakji4Eye Treatment Centre, Whipps Cross University Hospital, Barts Health National Health System Foundation Trust, Leytonstone, London E11 1NR, UKEye Treatment Centre, Whipps Cross University Hospital, Barts Health National Health System Foundation Trust, Leytonstone, London E11 1NR, UKEye Treatment Centre, Whipps Cross University Hospital, Barts Health National Health System Foundation Trust, Leytonstone, London E11 1NR, UKEye Treatment Centre, Whipps Cross University Hospital, Barts Health National Health System Foundation Trust, Leytonstone, London E11 1NR, UKEye Treatment Centre, Whipps Cross University Hospital, Barts Health National Health System Foundation Trust, Leytonstone, London E11 1NR, UKAIM: To report real-life data on the use of an intravitreal fluocinolone acetonide implant in the treatment of refractory diabetic macular edema (DME) in pars plana vitrectomized (PPV) and non-PPV eyes. METHODS: This was a comparative retrospective observational study of 23 eyes with chronic DME. Best-corrected visual acuity (BCVA) and central macular thickness (CMT) were recorded at baseline, 1, 4 and 12mo. Descriptive statistics and non-parametric tests were performed to analyze and compare PPV and non-PPV eyes. RESULTS: Seven PPV and 16 non-PPV eyes were included in the study. Median BCVA in the non-PPV group varied from 0.65 logMAR [Interquartile range (IQR): 0.40] at baseline to 0.42 logMAR (IQR: 0.40) at 12mo. Median CMT varied from 430 µm (IQR: 131.3) at baseline to 317 µm (IQR: 107.5) at 12mo. Median BCVA in the PPV group varied from 0.60 logMAR (IQR: 0.62) at baseline to 0.74 logMAR (IQR: 0.34) at 12mo. Median CMT varied from 483 µm (IQR: 146) at baseline to 397 µm (IQR: 132) at 12mo. Of 0/7 eyes and 1/16 eyes in the PPV and non-PPV eyes respectively had a baseline visual acuity of 6/12 or better (0.3 logMAR). At last follow up, 1/7 and 5/16 eyes in the PPV and non-PPV group respectively achieved a visual acuity of 6/12 or better. CONCLUSION: Visual outcomes are modest following the use of the fluocinolone acetonide implant for chronic DME. The steroid implant is a useful treatment option in the management of refractory DME in vitrectomized and non-vitrectmized eyes.http://www.ijo.cn/en_publish/2018/12/20181213.pdfdiabetic macular edemafluocinolone acetonideintravitreal implantsteroidvitrectomy |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Alberto La Mantia Alan Hawrami Heidi Laviers Sudeshna Patra Hadi Zambarakji |
spellingShingle |
Alberto La Mantia Alan Hawrami Heidi Laviers Sudeshna Patra Hadi Zambarakji Treatment of refractory diabetic macular edema with a fluocinolone acetonide implant in vitrectomized and non-vitrectomized eyes International Journal of Ophthalmology diabetic macular edema fluocinolone acetonide intravitreal implant steroid vitrectomy |
author_facet |
Alberto La Mantia Alan Hawrami Heidi Laviers Sudeshna Patra Hadi Zambarakji |
author_sort |
Alberto La Mantia |
title |
Treatment of refractory diabetic macular edema with a fluocinolone acetonide implant in vitrectomized and non-vitrectomized eyes |
title_short |
Treatment of refractory diabetic macular edema with a fluocinolone acetonide implant in vitrectomized and non-vitrectomized eyes |
title_full |
Treatment of refractory diabetic macular edema with a fluocinolone acetonide implant in vitrectomized and non-vitrectomized eyes |
title_fullStr |
Treatment of refractory diabetic macular edema with a fluocinolone acetonide implant in vitrectomized and non-vitrectomized eyes |
title_full_unstemmed |
Treatment of refractory diabetic macular edema with a fluocinolone acetonide implant in vitrectomized and non-vitrectomized eyes |
title_sort |
treatment of refractory diabetic macular edema with a fluocinolone acetonide implant in vitrectomized and non-vitrectomized eyes |
publisher |
Press of International Journal of Ophthalmology (IJO PRESS) |
series |
International Journal of Ophthalmology |
issn |
2222-3959 2227-4898 |
publishDate |
2018-12-01 |
description |
AIM: To report real-life data on the use of an intravitreal fluocinolone acetonide implant in the treatment of refractory diabetic macular edema (DME) in pars plana vitrectomized (PPV) and non-PPV eyes.
METHODS: This was a comparative retrospective observational study of 23 eyes with chronic DME. Best-corrected visual acuity (BCVA) and central macular thickness (CMT) were recorded at baseline, 1, 4 and 12mo. Descriptive statistics and non-parametric tests were performed to analyze and compare PPV and non-PPV eyes.
RESULTS: Seven PPV and 16 non-PPV eyes were included in the study. Median BCVA in the non-PPV group varied from 0.65 logMAR [Interquartile range (IQR): 0.40] at baseline to 0.42 logMAR (IQR: 0.40) at 12mo. Median CMT varied from 430 µm (IQR: 131.3) at baseline to 317 µm (IQR: 107.5) at 12mo. Median BCVA in the PPV group varied from 0.60 logMAR (IQR: 0.62) at baseline to 0.74 logMAR (IQR: 0.34) at 12mo. Median CMT varied from 483 µm (IQR: 146) at baseline to 397 µm (IQR: 132) at 12mo. Of 0/7 eyes and 1/16 eyes in the PPV and non-PPV eyes respectively had a baseline visual acuity of 6/12 or better (0.3 logMAR). At last follow up, 1/7 and 5/16 eyes in the PPV and non-PPV group respectively achieved a visual acuity of 6/12 or better.
CONCLUSION: Visual outcomes are modest following the use of the fluocinolone acetonide implant for chronic DME. The steroid implant is a useful treatment option in the management of refractory DME in vitrectomized and non-vitrectmized eyes. |
topic |
diabetic macular edema fluocinolone acetonide intravitreal implant steroid vitrectomy |
url |
http://www.ijo.cn/en_publish/2018/12/20181213.pdf |
work_keys_str_mv |
AT albertolamantia treatmentofrefractorydiabeticmacularedemawithafluocinoloneacetonideimplantinvitrectomizedandnonvitrectomizedeyes AT alanhawrami treatmentofrefractorydiabeticmacularedemawithafluocinoloneacetonideimplantinvitrectomizedandnonvitrectomizedeyes AT heidilaviers treatmentofrefractorydiabeticmacularedemawithafluocinoloneacetonideimplantinvitrectomizedandnonvitrectomizedeyes AT sudeshnapatra treatmentofrefractorydiabeticmacularedemawithafluocinoloneacetonideimplantinvitrectomizedandnonvitrectomizedeyes AT hadizambarakji treatmentofrefractorydiabeticmacularedemawithafluocinoloneacetonideimplantinvitrectomizedandnonvitrectomizedeyes |
_version_ |
1725298939259781120 |